3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
6
Not yet recruiting
2
Unknown
1
Suspended
1
Recruiting
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
550
Specimen Handling
462
Carboplatin
441
Magnetic Resonance Spectroscopy
429
Cyclophosphamide
412
Cisplatin
398
Radiotherapy
313
Gemcitabine
310
Bevacizumab
306
Paclitaxel
294
Biopsy
259
Drug Therapy
248
Capecitabine
241
Oxaliplatin
239
fludarabine
238
Nivolumab
224
venetoclax
219
Injections
213
Docetaxel
205
Fluorouracil
202
Dexamethasone
186
Radiosurgery
172
Rituximab
158
Pemetrexed
153
Standard of Care
145
durvalumab
143
Leucovorin
138
atezolizumab
137
toripalimab
134
tislelizumab
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Acetic Acid
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled